-
commercially available vaccines, sold
under the
brand names Dengvaxia and Qdenga.
Dengvaxia is only
recommended in
those who have
previously had dengue...
- The
Dengvaxia controversy (locally [dɛŋˈvakʃa])
occurred in the
Philippines when the
dengue vaccine Dengvaxia was
found to
increase the risk of disease...
-
Philippine Department of
Health that
Dengvaxia is safe and that the
initial deaths of
children were not
connected with
Dengvaxia.
Various organizations have blamed...
- of
dengue vaccine have been
approved and are
commercially available.
Dengvaxia became available in 2016 but it is only
recommended to
prevent re-infection...
- mosquito-borne diseases.
Dengvaxia,
developed by Sanofi-Pasteur, was the
first dengue vaccine available in the
United States.
Dengvaxia (CYD-TVD) is a live...
- as a
consultant and
later as a
scientific critic of
Sanofi Pasteur’s
Dengvaxia, the
first dengue vaccine to be
licensed for
widespread use in countries...
-
three regions to
vaccinate schoolchildren against dengue fever,
using Dengvaxia supplied by
Sanofi Pasteur. On 29
November 2017,
Sanofi issued a caution...
- adults,
adolescents and
children from four
years of age. The 2016
vaccine Dengvaxia is only
recommended in
individuals who have been
previously infected,...
-
previous to 74% at the time of the outbreak,
allegedly caused by the
Dengvaxia controversy. The
Department of
Health (DOH) of the
Philippines declared...
- mark,
Chemistry World,
Maria Burke, 29 July 2015 Sanofi's
Dengue Vaccine Dengvaxia Gains Brazilian Approval,
Zacks Equity Research, Zacks.com, 29 December...
